ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0147

ESKD Immunoglobulin Response at 3 Months Post COVID-19 Vaccination

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Choudhury, Devasmita, SAlem Veterans affairs medical Center, Salem, Virginia, United States
  • Karageorge, Lampros S., SAlem Veterans affairs medical Center, Salem, Virginia, United States
  • Hasan, Alia, SAlem Veterans affairs medical Center, Salem, Virginia, United States

End stage kidney disease (ESKD) patients (pts) remain at high risk for COVID 19 infection. Inadequate post infection antibody response is reported in 10-11% of pts1. Current data is limited on ESKD post vaccination (vac)2 We report 3-month (mo) post vac response of ESKD pts receiving 2 doses of either Moderna or Pfizer vaccines.


Twenty- six of 42 stable ESKD pts completed 2 doses of either Moderna or Pfizer vaccination at Salem VAMC or at their nursing home facility during mo 01/02- 2021. 17/42 were not vaccinated (7 declined, 2 with COVID 19 infection, 6 acutely hospitalized) during that time. Antibody immune response testing using ADVIA Centaur COV2G automated 2-step sandwich immunoassay using indirect chemiluminescent technology and designed to detect the SARS-CoV-2 surface spike protein receptor binding domain (S1RBD) was completed in 05/2021. Measures obtained included reactivity to total SARS CoV-ab (IgM+ IgG) and IgG separately.


Please see table 1 for results


ESKD vaccine response to COVID 19 after 3months was 96% for total immunoglobulin response (IgM and IgG) and 87.5% for total IgG antibody response compared to no reactivity in those nonvaccinated patients. Age and presence of diabetes did not significantly affect immune response. Approximately 12.5 % of patients had nonreactivity to IgG antibody after 3 months. Patients not developing an IgG response by 3 mo were found to have underlying immunosuppressive disease. ESKD with COVID 19 infection maintained IgG reactive response 3 months after active disease. Nonreactivity was seen in those neither infected nor vaccinated, suggesting that these patients have likely not been exposed to COVID 19 viral infection.


  • Veterans Affairs Support